Center-Authored Papers

Filters: Author is Alonzo, Todd A  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
A
Cooper TM, Franklin J, Gerbing RB, Alonzo TA, Hurwitz C, Raimondi SC, Hirsch B, Smith FO, Mathew P, Arceci RJ et al..  2012.  AAML03P1, a pilot study of the safety of gemtuzumab ozogamicin in combination with chemotherapy for newly diagnosed childhood acute myeloid leukemia: A report from the children's oncology group.. Cancer. 118(3):761-769. Abstract
Cooper TM, Alonzo TA, Gerbing RB, Perentesis JP, Whitlock JA, Taub JW, Horton TM, Gamis AS, Meshinchi S, Loken MR et al..  2014.  AAML0523: A report from the Children's Oncology Group on the efficacy of clofarabine in combination with cytarabine in pediatric patients with recurrent acute myeloid leukemia.. Cancer. Abstract
Tarlock K, Alonzo TA, Moraleda PP, Gerbing RB, Raimondi SC, Hirsch BA, Ravindranath Y, Lange B, Woods WG, Gamis AS et al..  2014.  Acute myeloid leukaemia (AML) with t(6;9)(p23;q34) is associated with poor outcome in childhood AML regardless of FLT3-ITD status: a report from the Children's Oncology Group.. British journal of haematology. Abstract
Kutny MA, Alonzo TA, Gerbing RB, Wang Y-C, Raimondi SC, Hirsch BA, Fu CH, Meshinchi S, Gamis AS, Feusner JH et al..  2017.  Arsenic Trioxide Consolidation Allows Anthracycline Dose Reduction for Pediatric Patients With Acute Promyelocytic Leukemia: Report From the Children's Oncology Group Phase III Historically Controlled Trial AAML0631.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. :JCO2016716183. Abstract
Sung L, Aplenc R, Alonzo TA, Gerbing RB, Wang Y-C, Meshinchi S, Gamis AS.  2016.  Association between Prolonged Neutropenia and Reduced Relapse Risk in Pediatric AML: A Report from the Children's Oncology Group.. International journal of cancer. Abstract
B
Moore AS, Alonzo TA, Gerbing RB, Lange BJ, Heerema NA, Franklin J, Raimondi SC, Hirsch BA, Gamis AS, Meshinchi S.  2013.  BIRC5 (survivin) splice variant expression correlates with refractory disease and poor outcome in pediatric acute myeloid leukemia: A report from the Children's Oncology Group.. Pediatric blood & cancer. Abstract
C
Pollard JA, Loken M, Gerbing RB, Raimondi SC, Hirsch BA, Aplenc R, Bernstein ID, Gamis AS, Alonzo TA, Meshinchi S.  2016.  CD33 Expression and Its Association With Gemtuzumab Ozogamicin Response: Results From the Randomized Phase III Children's Oncology Group Trial AAML0531.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. Abstract
Lamba JK, Chauhan L, Shin M, Loken MR, Pollard JA, Wang Y-C, Ries RE, Aplenc R, Hirsch BA, Raimondi SC et al..  2017.  CD33 Splicing Polymorphism Determines Gemtuzumab Ozogamicin Response in De Novo Acute Myeloid Leukemia: Report From Randomized Phase III Children's Oncology Group Trial AAML0531.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. :JCO2016712513. Abstract
Johnston DL, Alonzo TA, Gerbing RB, Aplenc R, Woods WG, Meshinchi S, Gamis AS.  2017.  Central nervous system disease in pediatric acute myeloid leukemia: A report from the Children's Oncology Group.. Pediatric blood & cancer. Abstract
Gamis AS, Alonzo TA, Perentesis JP, Meshinchi S.  2012.  Children's Oncology Group's 2013 blueprint for research: Acute myeloid leukemia.. Pediatric blood & cancer. Abstract
Mortland L, Alonzo TA, Walter RB, Gerbing RB, Mitra AK, Pollard JA, Loken MR, Hirsch B, Raimondi S, Franklin J et al..  2013.  Clinical Significance of CD33 Nonsynonymous Single-Nucleotide Polymorphisms in Pediatric Patients with Acute Myeloid Leukemia Treated with Gemtuzumab-Ozogamicin-Containing Chemotherapy.. Clinical cancer research : an official journal of the American Association for Cancer Research. 19(6):1620-1627. Abstract
Vujkovic M, Attiyeh EF, Ries RE, Horn M, Goodman EK, Ding Y, Kavcic M, Alonzo TA, Gerbing RB, Hirsch B et al..  2015.  Concordance of copy number alterations using a common analytic pipeline for genome-wide analysis of Illumina and Affymetrix genotyping data: a report from the Children's Oncology Group.. Cancer genetics. Abstract
Pollard JA, Alonzo TA, Loken M, Gerbing RB, Ho PA, Bernstein ID, Raimondi SC, Hirsch B, Franklin J, Walter RB et al..  2012.  Correlation of CD33 expression level with disease characteristics and response to gemtuzumab ozogamicin containing chemotherapy in childhood AML.. Blood. 119(16):3705-11. Abstract
Maxson JE, Ries RE, Wang Y-C, Gerbing RB, Kolb AE, Thompson SL, Guidry Auvil JM, Marra MA, Ma Y, Zong Z et al..  2016.  CSF3R mutations have a high degree of overlap with CEBPA mutations in pediatric AML.. Blood. 127(24):3094-3098.
Bhatla D, Gerbing RB, Alonzo TA, Conner H, Ross JA, Meshinchi S, Zhai X, Zamzow T, Mehta PA, Geiger H et al..  2009.  Cytidine deaminase genotype and toxicity of cytosine arabinoside therapy in children with acute myeloid leukemia.. British journal of haematology. 144(3):388-94. Abstract
D
Lacayo NJ, Alonzo TA, Gayko U, Rosen DB, Westfall M, Purvis N, Putta S, Louie B, Hackett J, Cohen AC et al..  2013.  Development and validation of a single-cell network profiling assay-based classifier to predict response to induction therapy in paediatric patients with de novo acute myeloid leukaemia: a report from the Children's Oncology Group.. British journal of haematology. 162(2):250-62. Abstract
Canner J, Alonzo TA, Franklin J, Freyer DR, Gamis A, Gerbing RB, Lange BJ, Meshinchi S, Woods WG, Perentesis J et al..  2013.  Differences in outcomes of newly diagnosed acute myeloid leukemia for adolescent/young adult and younger patients: A Report from the Children's Oncology Group.. Cancer. Abstract
Tarlock K, Alonzo TA, Loken MR, Gerbing RB, Ries RE, Aplenc R, Sung L, Raimondi S, Hirsch BA, Kahwash SB et al..  2017.  Disease Characteristics and Prognostic Implications of Cell Surface FLT3 Receptor (CD135) Expression in Pediatric Acute Myeloid Leukemia: A Report from the Children's Oncology Group.. Clinical cancer research : an official journal of the American Association for Cancer Research. Abstract
E
Laszlo GS, Alonzo TA, Gudgeon CJ, Harrington KH, Kentsis A, Gerbing RB, Wang Y-C, Ries RE, Raimondi SC, Hirsch BA et al..  2016.  Erratum to: High expression of myocyte enhancer factor 2C (MEF2C) is associated with adverse-risk features and poor outcome in pediatric acute myeloid leukemia: a report from the Children's Oncology Group.. Journal of hematology & oncology. 9(1):133.
F
Redell MS, Ruiz MJ, Gerbing RB, Alonzo TA, Lange BJ, Tweardy DJ, Meshinchi S.  2012.  FACS analysis of Stat3/5 signaling reveals sensitivity to G-CSF and IL-6 as a significant prognostic factor in pediatric AML: a Children's Oncology Group report.. Blood. Abstract
G
Gamis AS, Alonzo TA, Meshinchi S, Sung L, Gerbing RB, Raimondi SC, Hirsch BA, Kahwash SB, Heerema-McKenney A, Winter L et al..  2014.  Gemtuzumab Ozogamicin in Children and Adolescents With De Novo Acute Myeloid Leukemia Improves Event-Free Survival by Reducing Relapse Risk: Results From the Randomized Phase III Children's Oncology Group Trial AAML0531.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. Abstract
Guest EM, Aplenc R, Sung L, Raimondi SC, Hirsch BA, Alonzo TA, Gerbing RB, Wang Y-CJ, Kahwash SB, Heerema-McKenney A et al..  2017.  Gemtuzumab ozogamicin in infants with AML: results from the Children's Oncology Group trials, AAML03P1 and AAML0531.. Blood.
Tarlock K, Alonzo TA, Gerbing R, Raimondi SC, Hirsch BA, Sung L, Pollard JA, Aplenc R, Loken MR, Gamis A et al..  2015.  Gemtuzumab ozogamicin reduces relapse risk in FLT3/ITD acute myeloid leukemia: a report from the Children's Oncology Group.. Clinical cancer research : an official journal of the American Association for Cancer Research. Abstract
Lee GE, Sung L, Fisher BT, Sullivan KE, McWilliams T, Tobias JW, Meshinchi S, Alonzo TA, Gamis A, Aplenc R.  2013.  Gene Expression Profiling to Predict Viridans Group Streptococcal and Invasive Fungal Infection in Pediatric Acute Myeloid Leukemia: A Brief Report from the Children's Oncology Group.. Acta haematologica. 131(3):167-169.
Vujkovic M, Attiyeh EF, Ries RE, Goodman EK, Ding Y, Kavcic M, Alonzo TA, Wang Y-C, Gerbing RB, Sung L et al..  2017.  Genomic architecture and treatment outcome in pediatric acute myeloid leukemia: a Children's Oncology Group report.. Blood. Abstract